Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses
BackgroundDespite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Coronavirus Disease 2019 (COVID-19) clinical syndrome. Me...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , |
| التنسيق: | article |
| منشور في: |
2023
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.1016/j.heliyon.2023.e20155 https://www.sciencedirect.com/science/article/pii/S2405844023073632 http://hdl.handle.net/10576/51788 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1857415087577366528 |
|---|---|
| author | Mohammed I., Danjuma |
| author2 | Sayed, Rana Aboughalia, Maryam Hassona, Aseel Elsayed, Basant Selim Elshafei, Mohamed Elzouki, Abdelnaser |
| author2_role | author author author author author author |
| author_facet | Mohammed I., Danjuma Sayed, Rana Aboughalia, Maryam Hassona, Aseel Elsayed, Basant Selim Elshafei, Mohamed Elzouki, Abdelnaser |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammed I., Danjuma Sayed, Rana Aboughalia, Maryam Hassona, Aseel Elsayed, Basant Selim Elshafei, Mohamed Elzouki, Abdelnaser |
| dc.date.none.fl_str_mv | 2023-09-16 2024-02-14T06:02:40Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://dx.doi.org/10.1016/j.heliyon.2023.e20155 Danjuma, M. I., Sayed, R., Aboughalia, M., Hassona, A., Elsayed, B. S., Elshafei, M., & Elzouki, A. (2023). Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses. Heliyon. 2405-8440 https://www.sciencedirect.com/science/article/pii/S2405844023073632 http://hdl.handle.net/10576/51788 10 9 2405-8440 |
| dc.language.none.fl_str_mv | en |
| dc.publisher.none.fl_str_mv | Elsevier |
| dc.rights.none.fl_str_mv | http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | COVID-19 Colchicine Meta-analysis Mortality Umbrella |
| dc.title.none.fl_str_mv | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | BackgroundDespite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Coronavirus Disease 2019 (COVID-19) clinical syndrome. MethodsIn this umbrella review, we carried out a comprehensive search of PubMed, EMBASE, Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of Abstracts of Reviews of Effectiveness between January 1, 2020 and January 31, 2023 for systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine in patients with COVID-19. This was to ascertain the exact relationship between colchicine exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality and risk of bias assessment of the included reviews. ResultsWe included eighteen meta-analyses (n = 199,932 participants) in this umbrella review. Colchicine exposure was associated with an overall reduction of about 32% in the risk of mortality (odds ratio 0.68, confidence interval [CI] 0.58–0.78; I2 = 94%, p = 0.001). Further examination of pooled estimates of mortality outcomes by the quality effects model (corrected for the methodological quality and risk of bias of the constituent reviews) reported similar point estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%). ConclusionIn a pooled umbrella evaluation of published meta-analyses of COVID-19 patient cohorts, exposure to colchicine was associated with a reduction in overall mortality. Although it remains uncertain if this effect could potentially be attenuated or augmented by COVID-19 vaccination. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | qu_b488a26eb17ce8452c88fcb96ed84367 |
| identifier_str_mv | Danjuma, M. I., Sayed, R., Aboughalia, M., Hassona, A., Elsayed, B. S., Elshafei, M., & Elzouki, A. (2023). Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses. Heliyon. 2405-8440 10 9 |
| language_invalid_str_mv | en |
| network_acronym_str | qu |
| network_name_str | Qatar University repository |
| oai_identifier_str | oai:qspace.qu.edu.qa:10576/51788 |
| publishDate | 2023 |
| publisher.none.fl_str_mv | Elsevier |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| spelling | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analysesMohammed I., DanjumaSayed, RanaAboughalia, MaryamHassona, AseelElsayed, Basant SelimElshafei, MohamedElzouki, AbdelnaserCOVID-19ColchicineMeta-analysisMortalityUmbrellaBackgroundDespite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Coronavirus Disease 2019 (COVID-19) clinical syndrome. MethodsIn this umbrella review, we carried out a comprehensive search of PubMed, EMBASE, Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of Abstracts of Reviews of Effectiveness between January 1, 2020 and January 31, 2023 for systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine in patients with COVID-19. This was to ascertain the exact relationship between colchicine exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality and risk of bias assessment of the included reviews. ResultsWe included eighteen meta-analyses (n = 199,932 participants) in this umbrella review. Colchicine exposure was associated with an overall reduction of about 32% in the risk of mortality (odds ratio 0.68, confidence interval [CI] 0.58–0.78; I2 = 94%, p = 0.001). Further examination of pooled estimates of mortality outcomes by the quality effects model (corrected for the methodological quality and risk of bias of the constituent reviews) reported similar point estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%). ConclusionIn a pooled umbrella evaluation of published meta-analyses of COVID-19 patient cohorts, exposure to colchicine was associated with a reduction in overall mortality. Although it remains uncertain if this effect could potentially be attenuated or augmented by COVID-19 vaccination.Open Access funding provided by the Qatar National Library.Elsevier2024-02-14T06:02:40Z2023-09-16Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1016/j.heliyon.2023.e20155Danjuma, M. I., Sayed, R., Aboughalia, M., Hassona, A., Elsayed, B. S., Elshafei, M., & Elzouki, A. (2023). Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses. Heliyon.2405-8440https://www.sciencedirect.com/science/article/pii/S2405844023073632http://hdl.handle.net/10576/517881092405-8440enhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:qspace.qu.edu.qa:10576/517882024-07-23T15:52:49Z |
| spellingShingle | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses Mohammed I., Danjuma COVID-19 Colchicine Meta-analysis Mortality Umbrella |
| status_str | publishedVersion |
| title | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_full | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_fullStr | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_full_unstemmed | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_short | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_sort | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| topic | COVID-19 Colchicine Meta-analysis Mortality Umbrella |
| url | http://dx.doi.org/10.1016/j.heliyon.2023.e20155 https://www.sciencedirect.com/science/article/pii/S2405844023073632 http://hdl.handle.net/10576/51788 |